<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR18">
 <label>18.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Lawitz</surname>
    <given-names>E</given-names>
   </name>
   <name>
    <surname>Poordad</surname>
    <given-names>FF</given-names>
   </name>
   <name>
    <surname>Pang</surname>
    <given-names>PS</given-names>
   </name>
   <name>
    <surname>Hyland</surname>
    <given-names>RH</given-names>
   </name>
   <name>
    <surname>Ding</surname>
    <given-names>X</given-names>
   </name>
   <name>
    <surname>Mo</surname>
    <given-names>H</given-names>
   </name>
   <name>
    <surname>Symonds</surname>
    <given-names>WT</given-names>
   </name>
   <name>
    <surname>McHutchison</surname>
    <given-names>JG</given-names>
   </name>
   <name>
    <surname>Membreno</surname>
    <given-names>FE</given-names>
   </name>
  </person-group>
  <article-title>Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial</article-title>
  <source>Lancet</source>
  <year>2014</year>
  <volume>383</volume>
  <issue>9916</issue>
  <fpage>515</fpage>
  <lpage>523</lpage>
  <pub-id pub-id-type="doi">10.1016/S0140-6736(13)62121-2</pub-id>
  <pub-id pub-id-type="pmid">24209977</pub-id>
 </element-citation>
</ref>
